Treatment with the JAK1 inhibitor filgotinib or the spleen tyrosine kinase inhibitor lanraplenib does not significantly improve outcomes for people with cutaneous lupus erythematosus, indicate phase 2 study results.

Filgotinib showed sustained efficacy, and the safety profile of filgotinib longer term was similar to that in the phase 2 and 3 trials.

A post-hoc analysis of data from the TORTUGA trial shows that treatment with filgotinib is associated with beneficial changes in MRI structural lesions in people with ankylosing spondylitis.

In FINCH 1, filgotinib was compared with placebo, and in FINCH 2, filgotinib was compared with adalimumab and placebo.

medwireNews : The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of the Janus kinase (JAK)1 -selective inhibitor filgotinib for the treatment of rheumatoid arthritis (RA).

A pooled analysis of data from the FINCH 1–3 studies has shown that 24 weeks of filgotinib treatment is well tolerated by a broad group of patients with rheumatoid arthritis, with an adverse event profile similar to that of its comparators.

An exploratory biomarker analysis of the EQUATOR study suggests that filgotinib treatment leads to a reduction in inflammation in patients with moderate-to-severe psoriatic arthritis.

Analysis of data from the EQUATOR trial indicates that treatment with the selective Janus kinase 1 inhibitor filgotinib is associated with a significant improvement in health-related quality of life among patients with active psoriatic arthritis.

Filgotinib, given in combination with methotrexate, may be a promising treatment option for methotrexate-naïve patients with moderate-to-severe rheumatoid arthritis, indicate findings from the FINCH 3 trial.

Analysis of the EQUATOR trial has shown that patients treated with the Janus kinase inhibitor filgotinib for active psoriatic arthritis generally achieve a quick response that remains stable over time.

Rheumatoid arthritis patients with an inadequate response or intolerance to biologic DMARDs who are treated with the selective JAK1 inhibitor filgotinib are more likely to achieve a clinical response than those given placebo, phase III trial results suggest.

Rheumatoid arthritis patients with an inadequate response or intolerance to biologic DMARDs who are treated with the selective JAK1 inhibitor filgotinib are more likely to achieve a clinical response than those given placebo, phase III trial results suggest.

Findings from the phase III FINCH 1 trial suggest that use of the selective Janus kinase 1 inhibitor filgotinib may be beneficial for patients with rheumatoid arthritis and a previous inadequate response to methotrexate.

The selective janus kinase 1 inhibitor filgotinib has shown efficacy in patients with psoriatic arthritis with no new safety signals, show phase II data from the EQUATOR study.

The selective JAK 1 inhibitor filgotinib has shown efficacy in patients with psoriatic arthritis with no new safety signals, show phase II data from the EQUATOR study.

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

Findings from the phase II TORTUGA trial suggest that treatment with the JAK1 inhibitor filgotinib may be beneficial for patients with ankylosing spondylitis who have not responded to treatment with nonsteroidal anti-inflammatory drugs.

A total of 290,608 adverse events were reported from patients with RA, aged 18–75 years, between January 2011 and April 2022, of which 50,694 were for a JAK inhibitor (tofacitinib, baricitinib, upadacitinib, filgotinib) and 239,914 were for a TNF inhibitor (etanercept, adalimumab, infliximab, certolizumab pegol, golimumab).

Their study included data from 18 phase 2 and 3 randomized controlled trials involving baricitinib (n=6), peficitinib (n=5), tofacitinib (n=3), upadacitinib (n=2), or filgotinib (n=2).

Filgotinib (selective JAK1 inhibitor) EQUATOR: PsA Phase 2 Patient population: Moderate-to-severe PsA and an insufficient response or intolerance to at least one conventional DMARD Treatment groups: Filgotinib 200 mg/day or placebo for 16 weeks Status: Published https://clinicaltrials.gov/ct2/show/NCT03101670 As reported at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, and published in The Lancet in October 2018, the EQUATOR trial investigated the efficacy and safety profiles of the selective JAK1 inhibitor filgotinib in PsA patients from seven European countries.